Authors' recommendations: After considering the strength of the available evidence in relation to the safety, clinical effectiveness and cost-effectiveness of optical coherence tomography (OCT) for assessment of central retinal thickness in the presence of macular oedema secondary to central retinal vein occlusion for access to aflibercept, MSAC advises that it does not currently support public funding because of insufficiently presented evidence in relation to its roles in assessing oedema before using treatment and also in monitoring treatment and thus in relation to its cost-effectiveness. MSAC advised that existing data, appropriately analysed, would usefully inform a reconsideration. MSAC proposed that it would convene a stakeholder meeting in conjunction with PBAC to progress OCT-related applications, including by determining what data would help inform MSAC and PBAC. The stakeholder meeting should include ophthalmologists, consumers, OCT providers and the pharmaceutical companies who are lodging and planning applications for medicines to treat ocular diseases and which involve the use of OCT.

Project Status: Completed

Year Published: 2013

URL for published report: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1310-public

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Australia

Organisation Name: Medical Services Advisory Committee

Contact Address: MSAC (MDP 107), GPO Box 9848, Canberra, ACT 2601, Australia. Tel: +61 2 6289 6811; Fax: +61 2 6289 8799.

Contact Name: msac.secretariat@health.gov.au

Contact Email: msac.secretariat@health.gov.au

Copyright: <p>Medical Services Advisory Committee (MSAC)</p>